0001567619-19-007013.txt : 20190315
0001567619-19-007013.hdr.sgml : 20190315
20190315200323
ACCESSION NUMBER: 0001567619-19-007013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190314
FILED AS OF DATE: 20190315
DATE AS OF CHANGE: 20190315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crockett Thomas Andrew
CENTRAL INDEX KEY: 0001690920
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 19686501
MAIL ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN, SALISBURY
CITY: WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 200, STE. 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 200, STE. 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
doc1.xml
FORM 4
X0306
4
2019-03-14
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001690920
Crockett Thomas Andrew
C/O KALVISTA PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
1
1
0
0
CEO
Common Stock
2019-03-14
4
S
0
3000
30.1613
D
268510
D
The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.51 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/Benjamin Palleiko, Attorney-in-Fact
2019-03-15